Quick Answer
Aquestive Therapeutics, Inc. reported R&D Expense of $17.19 million for fiscal year 2025.
Aquestive Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $17.19M | -15.2% |
| 2024 | $20.28M | +54.8% |
| 2023 | $13.10M | -25.0% |
| 2022 | $17.48M | +2.5% |
| 2021 | $17.05M | -14.3% |
| 2020 | $19.89M | -3.3% |
| 2019 | $20.57M | -11.0% |
| 2018 | $23.11M | +4.4% |
| 2017 | $22.13M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.53M | -14.0% | +10.4% |
| June 30, 2025 | $4.11M | -1.4% | -23.4% |
| March 31, 2025 | $5.36M | -9.6% | +1.7% |
| September 30, 2024 | $5.27M | +64.9% | +26.6% |
| June 30, 2024 | $4.16M | +19.8% | -29.8% |
| March 31, 2024 | $5.93M | +67.2% | +85.6% |
| September 30, 2023 | $3.20M | -1.1% | -8.0% |
| June 30, 2023 | $3.47M | -33.2% | -2.1% |
- Aquestive Therapeutics, Inc. showed a decrease of -15.2% in R&D Expense compared to the prior fiscal year.
- Over the 2017–2025 period, Aquestive Therapeutics, Inc.’s r&d expense has declined by 22.3% (from $22.13 million to $17.19 million).
- The most recent figure is from Aquestive Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: